Novofine Autocover Safety Needle Versus BD Safety Glide

This study has been completed.

First Received on July 13, 2005. Last Updated on January 23, 2012 History of Changes

Sponsor:	Novo Nordisk
Information provided by:	Novo Nordisk
ClinicalTrials.gov Identifier:	NCT00121355

Purpose

This trial is conducted in the United States of Americal (USA). The aim of this trial is to examine whether nurses prefer to use the NovoFine® Autocover Needle or the BD Safety Glide (TM) Syringe (only) in a hospital setting. The number of needle stick injuries will also be evaluated and whether these hospital nurses prefer the safety features of the NovoFine® Autocover Needle versus those of the BD Safety Glide (TM) Syringe. The identified hospital nurses will evaluate the two types of needles during standard administration of insulin to patients being treated for diabetes.

Condition	Intervention	Phase
Healthcare Professionals Delivery Systems	Device: safety glide Device: autocover needle	Phase IV

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety Study Intervention Model: Crossover Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	An Open-Label, Multi-Center, Prospective Cross-Over Study of Preference and Safety of NovoFine® Autocover(TM) Needles Compared to BD Safety Glide (TM) Syringes in the Hospital Setting

Further study details as provided by Novo Nordisk:

Enrollment:	83
Study Start Date:	July 2005
Study Completion Date:	June 2006
Primary Completion Date:	June 2006 (Final data collection date for primary outcome measure)

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Hospital nurses with prior injection training without an infectious blood borne disease

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00121355

Locations

United States, New Jersey
Novo Nordisk Clinical Trial Call Center
Princeton, New Jersey, United States, 08540

Sponsors and Collaborators

Novo Nordisk

Investigators

Study Director:

Campbell Howard, MD

Novo Nordisk

More Information

Additional Information:

Clinical Trials at Novo Nordisk This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	Public Access to Clinical Trials, Novo Nordisk A/S
ClinicalTrials.gov Identifier:	NCT00121355 History of Changes
Other Study ID Numbers:	MS241-1674
Study First Received:	July 13, 2005
Last Updated:	January 23, 2012
Health Authority:	United States: Institutional Review Board

ClinicalTrials.gov processed this record on February 09, 2012